Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101

Molecular Cancer Therapeutics

Volumn 2, Issue 8, 2003, Pages 721-728

  Plumb, Jane A ^a   Finn, Paul W ^b   Williams, Robert J ^b   Bandara, Morwenna J ^b   Romero, M Rosario ^b   Watkins, Claire J ^b   La Thangue, Nicholas B ^b   Brown, Robert ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BioAlliance Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ACETYLATION; ANIMAL; APOPTOSIS; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HELA CELL; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; XENOGRAFT;

ACETYLATION; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HELA CELLS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 1642453460     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000. (Pubitemid 30046295)
2. Jacobson, S., and Pillus, L. Modifying chromatin and concepts of cancer. Cur. Opin. Genet. Dev., 9: 175-184, 1999. (Pubitemid 29158552)
3. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature (Lond.), 389: 349-352, 1997. (Pubitemid 27415209)
4. Luo, R. X., and Dean, D. C. Chromatin remodelling and transcriptional regulation. J. Natl. Cancer Inst. (Bethesda), 91: 1288-1294, 1999.
5. Brown, R., and Strathdee, G. Epigenomics and epigenetic therapy of cancer. Trends Mol. Med., 8 (Suppl.): S43-S48, 2002. (Pubitemid 34297078)
6. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug. Discov., 1: 287-299, 2002. (Pubitemid 37361445)
7. Marks, P. A., Richon, V. M., and Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. (Bethesda), 92: 1210-1216, 2000. (Pubitemid 30627729)
8. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., and Pavietich, N. P. Structure of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (Lond.), 401: 188-193, 1999. (Pubitemid 29436325)
9. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 265: 17174-17179, 1990.
10. Kim, Y. B., Lee, K-H., Sugita, K., Yoshida, M., and Horinouchi, S. Oxamflatin is a novel antitumour compound that inhibits mammalian histone deacetylase. Oncogene, 18: 2461-2470, 1999. (Pubitemid 29206159)
11. Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., and Richon, V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res., 60: 5165-5170, 2000.
12. Plumb, J. A., Williams, R. J., Finn, P. W., Bandara, M. J., Romero, M. R., Watkins, C. J., La Thangue, N. B., and Brown, R. Inhibition of tumour cell growth in vitro and in vivo by the histone deacetylase inhibitor PXD101. Proc. Am. Assoc. Cancer Res., 43: 333-334, 2002.
13. Plumb, J. A. Cell sensitivity assays: clonogenic assay. In: R. Brown and U. Boger-Brown (eds.), Cytotoxic Drug Resistance Mechanisms, pp. 17-23. Totowa, NJ: Humana Press, 1999.
14. Morton, D., and Griffiths, P. H. M. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet. Rec., 116: 431-436, 1985.
15. Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., and Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA, 95: 3003-3007, 1998. (Pubitemid 28135844)
16. Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., and Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nature Rev. Cancer (Phila.), 1: 194-202, 2001. (Pubitemid 33741894)
17. Mariadason, J. M., Corner, G. A., and Augenlicht, L. H. Genetic reprogramming in pathways of colon cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implication for chemoprevention of colon cancer. Cancer Res., 60: 4561-4572, 2000. (Pubitemid 32103641)
18. Jaboin, J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R., Bates, S. E., and Thiele, C. J. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric tumors. Cancer Res., 62: 6108-6115, 2002. (Pubitemid 35244459)
19. 1-phase progression. Genes Dev., 13: 1501-1512, 1999.
20. Munster, P. N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P. A., and Richon, V. M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res., 61: 8492-8497, 2001. (Pubitemid 33131130)
21. Wang, J., Saunthararajah, Y., Redner, R. L., and Liu, J. M. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res., 59: 2766-2769, 1999. (Pubitemid 29283104)
22. Strait, K. A., Dabbas. B., Hammond, E. H., Warnick, C. T., Iistrup, S. J., and Ford, C. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol. Cancer Ther., 1: 1181-1190, 2002.
23. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumour activity against human tumours. Proc. Natl. Acad. Sci. USA, 96: 4592-4597, 1999. (Pubitemid 29190381)
24. Plumb, J. A., Strathdee, G., Sludden, J., Kaye, S. B., and Brown, R. Reversal of drug resistance in human tumour xenografts by 2′-deoxy-5- azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res., 60: 6039-6044, 2000.
25. Carducci, M. A., Gilbert, J., Bowling, M. K., Noe, D., Eisenberg, M. A., Sinibaldi, V., Zebelina, Y., Chen, T-L., Grochow, L. B., and Donehower, R. C. Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120hr infusion schedule. Clin. Cancer Res., 7: 3047-3055, 2001. (Pubitemid 32963823)
26. Sandor, V., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R., Piekarz, R. L., Tucker, E., Figg, W. D., Chan, K. K., Goldspiel, B., Fojo, A. T., Balcerzak, S. P., and Bates, S. E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 63176), in patients with refactory neoplasms. Clin. Cancer Res., 8: 718-728, 2002. (Pubitemid 34742100)